The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Updated data on the safety and efficacy of BGB-16673 in R/R Waldenström’s macroglobulinemia
Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, presents data on BGB-16673, a BTK degrader, in the treatment of patients with relapsed/refractory (R/R) Waldenström’s macroglobulinemia. She notes significant preliminary antitumor activity with an overall response rate of 84% and improvements in cytopenia within two months of treatment. This data supports the use of BGB-16673 in this patient population. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in the last EHA meeting I presented the data on BGB-16673 that is a BTK degrader. So this is a new concept of BTK inhibition in which these agents actually degrade the BTK both with the wild type and the mutant form by tagging BTK for degradation through the cell-proteasome pathway. In the last follow-up, at 8.2 months, we observed that these agents had a significant preliminary antitumor activity that was demonstrated by a high efficacy with an overall response rate of 84% and about one third of patients achieving a VGPR, so a deep response...
So in the last EHA meeting I presented the data on BGB-16673 that is a BTK degrader. So this is a new concept of BTK inhibition in which these agents actually degrade the BTK both with the wild type and the mutant form by tagging BTK for degradation through the cell-proteasome pathway. In the last follow-up, at 8.2 months, we observed that these agents had a significant preliminary antitumor activity that was demonstrated by a high efficacy with an overall response rate of 84% and about one third of patients achieving a VGPR, so a deep response. And these responses were really rapid. We could see it by the time to first response, this was in median one month. And the improvement, the significant improvement in responding patients for cytopenia. So they showed a recovery of cytopenia in about two months of treatment. So all this data, in particular in this kind of population of heavily treated patients with the enriched for high-risk genomic aberration for Waldenstrom, supported the use of these drugs in dissecting or relapsed refractory patients with Waldenstrom after covalent BTK inhibitor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Beigene, Janssen, Abbvie, AstraZeneca.
